Information Provided By: 
Fly News Breaks for February 23, 2017
UTHR
Feb 23, 2017 | 07:33 EDT
Oppenheimer analyst Hartaj Singh raised his price target for United Therapeutics to $175 from $160, saying that visibility on the risk mitigation for patent losses is increasing, sales of the treprostinil franchise are potentially troughing, and now the timing of a key catalyst for oral product Orenitram has moved up. The analyst reiterates an Outperform rating on the shares.
News For UTHR From the Last 2 Days
There are no results for your query UTHR
